![‘Chicago Med’ Recap Season 10, Episode 8 — [Spoiler] Dead or Alive](https://tvline.com/wp-content/uploads/2024/11/chicago-med-recap.jpg?w=650 "‘Chicago Med’ Recap Season 10, Episode 8 — [Spoiler] Dead or Alive")
Kenvue CEO Thibaut Mongon at the New York Stock Exchange for its initial public offering, May 4, 2023.
Source: NYSE
Activist investor Starboard Value has a large stake in Kenvue, which spun out of Johnson & Johnson in mid-2023, according to people familiar with the matter.
The activist is looking for the company to improve its share price, said the people, who requested anonymity to discuss private information freely. CNBC could not learn size of the stake nor Starboard’s specific plans. Starboard’s Jeff Smith is expected to discuss the activist’s plans for the company in detail at 13D Monitor’s Active-Passive Investor Summit on Tuesday.
Shares surged roughly 8% in pre-market trading Monday on the news, which was first reported by The Wall Street Journal.
Kenvue is the maker of iconic brands familiar to both investors and the broader public, such as Aveeno, Band-Aid, Listerine, Neutrogena, Tylenol and J&J’s namesake baby powder and shampoo.
Starboard’s push at Kenvue comes just two weeks after news broke it had amassed a roughly $1 billion stake in struggling pharmaceutical company Pfizer.
Johnson & Johnson completed its separation from Kenvue in August last year, though the pharmaceutical giant still holds a stake in the new company. It marked the biggest shake-up in J&J’s nearly 140-year history.
J&J announced the split in late 2021 as a bid to streamline operations and refocus on its pharmaceutical and medical device divisions.
